Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eucorvac-19
- Development stage
- Phase 3
- Lead developer
- EuBiologics
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
EuCorVac-19 is a recombinant protein subunit COVID-19 vaccine developed by EuBiologics. It displays the receptor binding domain (RBD) of the SARS-CoV‑2 spike protein, derived from the Wuhan strain, on immunogenic liposomes using proprietary technology. The antigen component, EulMT, is in‑licensed from Korea Institute of Science and Technology and formulated with SNAP technology licensed from POP Biotechnologies. The vaccine is administered intramuscularly and has demonstrated favorable safety and immunogenicity profiles in clinical trials, including strong anti-RBD IgG responses and neutralizing antibody titers against both original SARS-CoV‑2 strains and variants such as Omicron. Its primary indication is for prevention of COVID‑19[1][2][4][8].
- Other names
- covid19 vaccine (eubiologics)sars-cov-2 spike protein vaccine (recombinant) (eubiologics)
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on eucorvac-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eucorvac-19.